In this regard, it has been shown that co-treatment of the HDACi panobinostat and the JAK2 inhibitor TG101209 resulted in greater attenuation of JAK/STAT signaling in human and mouse JAK2V617F-mutated cells and increased cytotoxicity against MPN CD34+ cells compared to individual drugs [28]. Here, JAK2 is linked to myeloproliferative neoplasm.